EE03661B1 - Vähendatud viskoossusega oftalmoloogiline kompositsioon - Google Patents

Vähendatud viskoossusega oftalmoloogiline kompositsioon

Info

Publication number
EE03661B1
EE03661B1 EE9600120A EE9600120A EE03661B1 EE 03661 B1 EE03661 B1 EE 03661B1 EE 9600120 A EE9600120 A EE 9600120A EE 9600120 A EE9600120 A EE 9600120A EE 03661 B1 EE03661 B1 EE 03661B1
Authority
EE
Estonia
Prior art keywords
amount
pct
weight
viscosity
composition
Prior art date
Application number
EE9600120A
Other languages
English (en)
Other versions
EE9600120A (et
Inventor
Reunam�ki Timo
Lehmussaari Kari
Vartiainen Eija
Oksala Olli
Alaranta Sakari
Pohjala Esko
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of EE9600120A publication Critical patent/EE9600120A/et
Publication of EE03661B1 publication Critical patent/EE03661B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EE9600120A 1994-03-31 1995-03-29 Vähendatud viskoossusega oftalmoloogiline kompositsioon EE03661B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401108A SE9401108D0 (sv) 1994-03-31 1994-03-31 Ophthalmic composition I
PCT/FI1995/000166 WO1995026711A1 (en) 1994-03-31 1995-03-29 Ophthalmic composition with decreased viscosity

Publications (2)

Publication Number Publication Date
EE9600120A EE9600120A (et) 1997-04-15
EE03661B1 true EE03661B1 (et) 2002-04-15

Family

ID=20393511

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600120A EE03661B1 (et) 1994-03-31 1995-03-29 Vähendatud viskoossusega oftalmoloogiline kompositsioon

Country Status (27)

Country Link
US (1) US5710182A (et)
EP (1) EP0752847B1 (et)
JP (1) JPH10503470A (et)
KR (1) KR100365914B1 (et)
CN (1) CN1112918C (et)
AT (1) ATE202921T1 (et)
AU (1) AU694497B2 (et)
BG (1) BG63145B1 (et)
BR (1) BR9507438A (et)
CA (1) CA2186734A1 (et)
CZ (1) CZ290987B6 (et)
DE (2) DE69521686T2 (et)
DK (1) DK0752847T3 (et)
EE (1) EE03661B1 (et)
ES (1) ES2161874T3 (et)
GR (1) GR3036763T3 (et)
HK (1) HK1013953A1 (et)
HU (1) HU223071B1 (et)
MX (1) MX9603918A (et)
NO (1) NO314434B1 (et)
PL (1) PL179433B1 (et)
PT (1) PT752847E (et)
RO (1) RO115409B1 (et)
RU (1) RU2139016C1 (et)
SE (1) SE9401108D0 (et)
SK (1) SK280492B6 (et)
WO (1) WO1995026711A1 (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718568D0 (en) 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
AU4808000A (en) 1999-04-28 2000-11-10 Situs Corporation Drug delivery system
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
CN1638734A (zh) * 2002-02-22 2005-07-13 参天制药株式会社 微粒结膜下给药的药物释放系统
AU2003213210A1 (en) * 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
KR20050085367A (ko) * 2002-12-04 2005-08-29 산텐 세이야꾸 가부시키가이샤 결막하 데포에 의한 약물 송달 시스템
JP2004196787A (ja) * 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
KR20110134525A (ko) * 2003-06-13 2011-12-14 알콘, 인코퍼레이티드 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI347847B (en) * 2003-08-20 2011-09-01 Santen Pharmaceutical Co Ltd Drug delivery system for sub-tenon administration of fine particles
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
DE102005035986B4 (de) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
US20110190323A1 (en) * 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
WO2012108489A1 (ja) * 2011-02-10 2012-08-16 参天製薬株式会社 親水性薬物の薬物移行性を改善した水性組成物
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
EP3505521A1 (en) 2013-12-24 2019-07-03 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CA3014774A1 (en) 2016-02-17 2017-08-24 Children's Medical Center Corporation Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CA3031370A1 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
WO2018160889A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
SG11201910085UA (en) * 2017-05-11 2019-11-28 Nevakar Inc Atropine pharmaceutical compositions
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
EP4288049A1 (en) * 2021-02-04 2023-12-13 Sydnexis, Inc. Ophthalmic compositions for presbyopia
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113786380A (zh) * 2021-09-18 2021-12-14 华北制药股份有限公司 一种硝酸毛果芸香碱眼用凝胶及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.

Also Published As

Publication number Publication date
EP0752847A1 (en) 1997-01-15
NO964070L (no) 1996-11-28
EE9600120A (et) 1997-04-15
AU2138995A (en) 1995-10-23
KR100365914B1 (ko) 2003-04-16
RO115409B1 (ro) 2000-02-28
CZ286596A3 (en) 1997-04-16
BG63145B1 (bg) 2001-05-31
HU223071B1 (hu) 2004-03-01
CN1144477A (zh) 1997-03-05
DE69521686T2 (de) 2002-04-25
WO1995026711A1 (en) 1995-10-12
EP0752847B1 (en) 2001-07-11
BG100915A (en) 1997-07-31
SK280492B6 (sk) 2000-03-13
CZ290987B6 (cs) 2002-11-13
NO964070D0 (no) 1996-09-27
CN1112918C (zh) 2003-07-02
HU9602691D0 (en) 1996-11-28
US5710182A (en) 1998-01-20
DK0752847T3 (da) 2001-10-22
SE9401108D0 (sv) 1994-03-31
KR970702024A (ko) 1997-05-13
AU694497B2 (en) 1998-07-23
NO314434B1 (no) 2003-03-24
ES2161874T3 (es) 2001-12-16
PL179433B1 (pl) 2000-09-29
PT752847E (pt) 2001-12-28
GR3036763T3 (en) 2001-12-31
SK123996A3 (en) 1997-06-04
JPH10503470A (ja) 1998-03-31
PL316584A1 (en) 1997-01-20
BR9507438A (pt) 1997-09-16
HUT75666A (en) 1997-05-28
MX9603918A (es) 1997-04-30
RU2139016C1 (ru) 1999-10-10
CA2186734A1 (en) 1995-10-12
ATE202921T1 (de) 2001-07-15
DE752847T1 (de) 1997-09-04
DE69521686D1 (de) 2001-08-16
HK1013953A1 (en) 1999-09-17

Similar Documents

Publication Publication Date Title
EE03661B1 (et) Vähendatud viskoossusega oftalmoloogiline kompositsioon
SE9401109D0 (sv) Opthalmic composition II
US5945121A (en) Liposome eye drops
AU625099B2 (en) Aqueous antimicrobial ophthalmic solutions
KR960700081A (ko) 콘택트렌즈 용액 보존 시스템(preservative system for contact lens solutions)
WO1998005365A3 (en) Compositions and methods for disinfecting contact lenses and preserving contact lens care products
CA2183547A1 (en) Compositions for treating defective cell functions
DE60012068D1 (de) Zusammensetzung mit kontinuierlicher wässeriger Phase, die L-2-Oxothiazolidin- 4-carbonsäure enthält".
WO2009006130A3 (en) Salt free hyaluronate ophthalmic solution
DE3625867C2 (de) Verwendung von Tetrachlordecaoxid in der Ophthalmologie
JPS6452727A (en) Antiallergic eye drop
FI963744A (fi) Alennetun viskositeetin omaava oftalminen koostumus
AU2001242398A1 (en) Contact lens treating method and composition
JPS6217973B2 (et)

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231